• Caselli, Richard John (PI)
  • Kaszniak, Alfred W. (PI)
  • Alexander, Gene (PI)
  • Kaszniak, Alfred W. (PI)
  • Beach, Thomas (PI)
  • Kaszniak, Alfred W. (PI)
  • Reiman, Eric Michael (PI)
  • Beach, Thomas (PI)
  • Kaszniak, Alfred W. (PI)
  • Coon, David (PI)
  • Gonzalez Hernandez, Graciela (PI)
  • Bimonte-Nelson, Heather A. (PI)

Project: Research project

Project Details


DESCRIPTION (provided by applicant):
The proposed Clinical Core will identify and follow 500 patients at all stages
of Alzheimer's disease (AD) and related dementing illnesses, 100 patients with
mild cognitive impairment, and 300 elderly controls who come from anywhere in
the state of Arizona. All subjects will undergo a diagnostic battery of tests
providing information and data from demographic, historical, medical,
neurological, psychiatric, and neuropsychological measures. Based on strict
entrance criteria, eligible patients will be discussed in a diagnostic
consensus conference and then offered enrollment in the research center.
Enrolled research subjects will undergo apolipoprotein E (APOE) genotyping,
and a standard neuropsychological battery, which will be administered at all
clinical sites to all patient and control subjects. The enrollees will be
screened for potential participation in ongoing and developing research
projects involving brain imaging, neuropathology, neuropsychology, natural
history of aging and dementia, genetics of disease, therapeutic trials, and
predictive modeling. All will be enrolled in the brain donation program for
neuropathological confirmation of clinical diagnoses.
The proposed Clinical Core capitalizes on several unique strengths that
enhance our feasibility for achieving our patient recruitment goals, including
a large catchment area represented by all the major tertiary care referral
centers throughout the state of Arizona, the availability of existing cohorts
of longitudinally studied dementia patients and age matched controls already
committed to participation in our brain bank program, regional access to
Hispanic and Native American populations through community outreach and
educational services, availability of an existing cohort of cognitively normal
individuals at genetic risk for AD with the APOE 4 genotype from a
separately-funded ongoing longitudinal study, and demonstrated expertise in
the diagnosis and clinical study of patients with dementia syndromes and mild
cognitive impairment.
Effective start/end date7/1/016/30/21


  • Medicine(all)